Importantly, in patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, PD-1 inhibition was associated with longer progression-free and overall survival than platinum-based chemotherapy [11]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.